Dr Jose-Carlos Gutiérrez-Ramos is the Chief Science Officer at Danaher Corporation. He has held senior drug discovery roles at Pfizer,…
JERSEY CITY, N.J., Jan. 9, 2025 /PRNewswire/ -- Outcomes Matter Innovations, LLC ("OMI") today announced a co-development agreement with Regional…
Dark genome biotech company RyboDyn closes pre-seed fundraise from leading global investors to advance cancer immunotherapy SAN DIEGO, Jan. 9,…
Stevens brings decades of healthcare leadership and innovation to TechBio company at the forefront of advancing digital precision medicine to…
Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025…
-- Enrollment Completed Ahead of Schedule -- -- Initial Data Expected in 2025 -- NEW YORK, Jan. 09, 2025 (GLOBE…
FMC-220 is a first-in-class covalent activator of p53Y220C designed to address potency and tolerability challenges of non-covalent approachesIn preclinical studies,…
The panel will discuss the value proposition for investing in women’s health. J.P. Morgan is hosting a three-panel women’s health…
Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a…
World-renowned researcher brings expertise in obstetrics and gynecology from Yale University to advance Eterna’s lead indication in ovarian cancerCAMBRIDGE, Mass.,…